Open AccessCancer vaccine adjuvants
Author(s) -
М А Барышникова,
В. С. Косоруков
Publication year - 2019
Publication title -
rossijskij bioterapevtičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 1726-9792
pISSN - 1726-9784
DOI - 10.17650/1726-9784-2018-17-4-36-44
Subject(s) - immune system , adjuvant , vaccine adjuvant , immunotherapy , cancer vaccine , medicine , vaccination , immunology , cancer immunotherapy , antigen , clinical trial , cancer
Adjuvants are important components of cancer vaccines because they enhance immune responses to vaccination. However, adjuvants licensed for clinical use, e. g. aluminum salts, fail to stimulate an effective immune response. Research and development of new adjuvants with combined functions, including immune stimulation and antigen delivery, are a vital task for antitumor immunotherapy. Clinical trials of immune stimulating compounds, in particular Toll-like receptor (TLR) ligands, reveal their therapeutic potential as both antitumor agents and vaccine adjuvants.